Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Promising vaccine may provide long-lasting protection against malaria


Researchers have developed a unique vaccine that destroys a deadly toxin produced by the parasite that causes malaria, which kills more than two million people each year. The vaccine appears extremely promising in animal studies, they say.

If the drug works in humans, it could become a more effective and longer lasting anti-malarial vaccine than those currently available, according to the researchers.

Details of the research will be presented next week (Aug. 21) in Boston at the 224th national meeting of the American Chemical Society, the world’s largest scientific society. The study will be published in the Aug. 15 issue of Nature.

"This research represents an exciting new approach to controlling malaria by blocking the toxin that is responsible for so many deaths," says Peter H. Seeberger, Ph.D., associate professor of chemistry at the Massachusetts Institute of Technology in Cambridge, Mass. "We hope that this is the answer, but we don’t know yet."

Tests of the new vaccine in monkeys are slated to begin soon, while tests on humans could begin within two years, said Seeberger, who is co-leader of the study along with his colleague, Louis Schofield, Ph.D., of the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia.

Although other vaccines have been developed and tested against malaria, none lasts for more than a few weeks. Most target proteins on the surface of the parasite, which has the ability to change its surface proteins and eventually resist the vaccine, according to Seeberger.

The new vaccine targets the toxin instead of the parasite. Although the parasite itself lives, it is rendered harmless by the destruction of its deadly toxin, he said.

One or two shots of the vaccine are expected to provide lasting protection against the disease. If necessary, its effectiveness could be enhanced by using it in combination with other vaccines that target the malarial parasite, Seeberger said.

Malaria is a life-threatening parasitic disease transmitted by the bite of the female Anopheles mosquito, which transfers deadly one-celled parasites to human blood in an effort to nurture her eggs. The disease can be caused by one of four different parasites. The most lethal is Plasmodium falciparum, which is also responsible for the majority of infections.

Louis Schofield recently discovered that, as part of its life cycle inside its human host, the parasite releases an inflammatory toxin that appears to trigger the fever, convulsions and deaths associated with the disease.

Previous studies by Seeberger’s colleagues demonstrated that small amounts of the toxin — a tiny carbohydrate molecule called GPI — could be used to effectively immunize mice against infection and reduce fatalities. But the human immune system does not recognize such small molecules as foreign and cannot make antibodies to destroy them.

Seeberger and Schofield designed a synthetic version of the toxin and attached it to a protein molecule in hopes that the newly created complex would be large enough for the body to recognize so that an immune response could be launched against it.

When a group of healthy, unvaccinated mice were injected with blood containing a deadly malarial parasite, all died. But when the synthetic toxin was injected into a group of healthy mice and they were subsequently injected with the parasite, 65 to 95 percent survived.

The immunized mice also had enhanced protection from severe inflammatory conditions associated with the disease, including swelling of the brain, the researchers found.

Seeberger and his colleagues are continuing to refine their vaccine formulations to achieve a 100 percent survival rate. They hope that similar results will be seen in people.

According to the World Health Organization (WHO), malaria is one of the major public health problems, along with HIV/AIDS and tuberculosis, in the poorest regions of the world. More than 90 percent of deaths from malaria occur in Africa, mostly among infants and young children. It is estimated that the disease kills one African child every 30 seconds.

More recently, a dramatic surge in the number of malaria cases occurring among U.S. travelers to areas where the disease is common has been reported.

Funding for this research was provided by the National Institutes of Health, the United Nations Development Programme/World Bank/WHO Special Program for Research and Training in Tropical Diseases, the Human Frontiers of Science Program, the Howard Hughes Medical Institute, and the Australian National Health & Medical Research Council.

The paper on this research, CARB 81, will be presented at 9:25 a.m., Wednesday, Aug. 21, at Sheraton Boston, Republic B, during the symposium, "Carbohydrate Immunology and Therapeutics."

Peter H. Seeberger, Ph.D., is an associate professor of chemistry in the department of chemistry at Massachusetts Institute of Technology in Cambridge, Mass.

Louis Schofield, Ph.D., is a researcher at the Walter & Eliza Hall Institute of Medical Research in Melbourne, Australia.

Mark T. Sampson

Beverly Hassell | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Generation of a Stable Biradical

22.03.2018 | Life Sciences

Scientists develop a room temperature maser to amplify weak signals

22.03.2018 | Life Sciences

Jacobs University supports new mapping of Mars, Mercury and the Moon

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>